Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Immucell ( (ICCC) ).
ImmuCell Corporation announced significant leadership changes effective November 1, 2025, with Olivier te Boekhorst assuming the roles of President and CEO, succeeding Michael F. Brigham, who will continue as a Special Advisor to the CEO until January 2026. The company’s Board of Directors expanded from seven to nine members, appointing Mr. te Boekhorst and CFO Timothy C. Fiori as new directors. These changes are part of ImmuCell’s strategic efforts to enhance its market position and drive growth, particularly in advancing the First Defense® franchise and completing the development of Re-Tain®.
The most recent analyst rating on (ICCC) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Immucell stock, see the ICCC Stock Forecast page.
Spark’s Take on ICCC Stock
According to Spark, TipRanks’ AI Analyst, ICCC is a Neutral.
Immucell’s overall stock score reflects a mixed financial performance with some growth potential but significant profitability challenges. The strong earnings call performance, with notable sales and margin improvements, positively impacts the score. However, technical indicators suggest a lack of momentum, and the valuation appears high, which tempers the overall outlook.
To see Spark’s full report on ICCC stock, click here.
More about Immucell
ImmuCell Corporation is a growing animal health company focused on developing, manufacturing, and marketing scientifically proven and practical products that enhance the health and productivity of dairy and beef cattle. The company offers products like First Defense®, which provides immediate immunity to newborn calves, and is in the late stages of developing Re-Tain®, a treatment for subclinical mastitis in dairy cows that does not require milk discard or pre-slaughter withdrawal.
Average Trading Volume: 14,662
Technical Sentiment Signal: Buy
Current Market Cap: $56.17M
See more insights into ICCC stock on TipRanks’ Stock Analysis page.